Scienmag

MARCH 25, 2021

Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases Credit: Insilico Medicine Thursday, 25th of March 2021 (5:00AM EST) — Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for […].

Medicine 76

Medicine Development Drugs Bioinformatics 76

Scienmag

JUNE 22, 2021

Credit: Insilco June 22, 2021, New York / Hong Kong — Insilico Medicine, a global leader in end-to-end artificial intelligence for target discovery, small molecule chemistry, and clinical development, announced that it has closed a $255 million from biotechnology experts to progress Insilico Medicine’s current therapeutic programs into (..)

Medicine 55

Medicine Clinical Trials Clinical Trials Clinical Development 55

Scienmag

AUGUST 20, 2020

GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma Credit: Insilico Medicine August 20th, 2020, Hong Kong – Researchers from Johns Hopkins University in collaboration with Insilico Medicine announce the publication of a new research paper titled “GULP1 regulates the NRF2-KEAP1 signaling axis in urothelial carcinoma” (..)

Regulation 52

Regulation Medicine Research Bioinformatics 52

Scienmag

NOVEMBER 9, 2020

Credit: Insilico Tuesday, November 10, 2020 (9AM Beijing) – Insilico Medicine, a leader in deep generative reinforcement learning for target discovery, small molecule generation, and prediction of clinical trial outcomes, today announced that it entered into a multi-target drug discovery agreement with Janssen Pharmaceutica N.V.

Drugs 53

Drugs Clinical Trials Clinical Trials Medicine 53